Hospital
Banner Ironwood Medical Center
Banner Ironwood Medical Center was paid $29.40M by Medicaid between Jan 2018 and Dec 2024, across 189 billing codes. Its largest line is 99285, emergency room visit (most serious) — 26% of everything it billed.
33Billing provider infoBANNER IRONWOOD MEDICAL CENTER
QUEEN CREEK, AZ 85140
QUEEN CREEK, AZ 85140
33aNPI1124341672assigned 03/11/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.40M
24GClaims585,233
24DCodes billed189
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#17 of 78
Median peer was paid$12.21M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,600 | $4.95M | |
| 2019 | 87,156 | $5.01M | |
| 2020 | 62,972 | $3.60M | |
| 2021 | 72,430 | $3.63M | |
| 2022 | 87,523 | $4.07M | |
| 2023 | 100,749 | $4.36M | |
| 2024incomplete | 83,803 | $3.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 26% | 18,220 | 16,397 | $7.74M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 25,901 | 23,800 | $7.10M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 19,044 | 17,991 | $4.71M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 14% | 5,493 | 5,162 | $4.01M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.6% | 3,284 | 3,052 | $1.64M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 5,839 | 5,538 | $868K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 5,468 | 5,086 | $826K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.7% | 1,554 | 1,459 | $487K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.4% | 352 | 322 | $412K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 1,200 | 1,121 | $411K |
| G0378 | Hospital observation service, per hour | <1% | 4,296 | 2,195 | $154K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,976 | 5,055 | $138K |
177 more codes
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 984 | $136K |
| 70496 | <1% | 168 | $113K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,024 | $103K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,390 | $78K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 256 | $47K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 887 | $44K |
| 93971 | <1% | 793 | $42K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,518 | $38K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,976 | $35K |
| 80053 | Comprehensive metabolic panel | <1% | 32,903 | $27K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,353 | $18K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 141 | $16K |
| 80320 | <1% | 3,594 | $14K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,084 | $13K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,320 | $13K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,028 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,470 | $11K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 17 | $9K |
| 74018 | <1% | 1,409 | $8K | |
| 73030 | <1% | 1,080 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,786 | $7K |
| 70498 | <1% | 193 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,590 | $6K |
| 73562 | <1% | 1,316 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,100 | $6K |
| 43235 | <1% | 12 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,243 | $6K |
| 73130 | <1% | 915 | $6K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,085 | $6K |
| 87631 | <1% | 1,762 | $6K | |
| 93976 | <1% | 2,052 | $5K | |
| 96376 | <1% | 5,068 | $4K | |
| 72100 | <1% | 393 | $4K | |
| 73630 | <1% | 998 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,183 | $3K |
| 73610 | <1% | 1,044 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,523 | $3K |
| J3490 | Unclassified drugs | <1% | 20,111 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 35,485 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,991 | $2K |
| 70486 | <1% | 28 | $2K | |
| 73110 | <1% | 379 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,850 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,427 | $1K |
| 83690 | <1% | 13,017 | $1K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 16 | $973.46 |
| 81025 | <1% | 7,973 | $965.86 | |
| 87081 | <1% | 804 | $909.49 | |
| 84484 | <1% | 10,537 | $898.90 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 19 | $853.43 |
| 81001 | <1% | 14,221 | $758.22 | |
| 82947 | <1% | 8,862 | $731.08 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 376 | $730.06 |
| 83605 | <1% | 5,361 | $615.97 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,704 | $576.19 |
| 87186 | <1% | 1,839 | $533.61 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,200 | $524.67 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,221 | $485.77 |
| 84703 | <1% | 2,955 | $484.96 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 314 | $462.71 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,139 | $456.57 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $309.60 |
| 84702 | <1% | 2,989 | $308.98 | |
| 83880 | <1% | 1,550 | $291.80 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,224 | $291.48 |
| 73502 | <1% | 41 | $291.22 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,324 | $291.01 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 18,908 | $278.19 |
| 83735 | <1% | 5,549 | $252.19 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 507 | $245.34 |
| 85055 | <1% | 157 | $244.15 | |
| 87040 | <1% | 4,053 | $238.44 | |
| 87088 | <1% | 5,363 | $229.76 | |
| 87077 | <1% | 2,399 | $227.78 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,273 | $223.02 |
| 71101 | <1% | 16 | $202.87 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,304 | $189.86 |
| 85379 | <1% | 1,470 | $188.91 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,593 | $171.33 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,368 | $152.79 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 3,350 | $135.22 |
| 86769 | <1% | 276 | $128.88 | |
| 81003 | <1% | 7,601 | $120.68 | |
| 76801 | <1% | 779 | $111.71 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,316 | $105.78 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,585 | $96.19 |
| 85610 | <1% | 4,651 | $92.66 | |
| 90715 | <1% | 246 | $91.41 | |
| 85027 | <1% | 2,877 | $88.47 | |
| 86850 | <1% | 1,671 | $86.12 | |
| 12011 | <1% | 25 | $84.29 | |
| 82550 | <1% | 1,102 | $83.09 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 835 | $74.20 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 305 | $55.56 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,040 | $52.52 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 150 | $51.29 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 153 | $51.29 |
| A9270 | Non-covered item or service | <1% | 11,625 | $51.03 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 373 | $48.22 |
| 87807 | <1% | 404 | $47.91 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,004 | $46.97 |
| 86901 | <1% | 2,270 | $46.03 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,467 | $43.54 |
| 86900 | <1% | 1,823 | $39.26 | |
| 86140 | <1% | 1,659 | $36.67 | |
| 82803 | <1% | 158 | $23.54 | |
| 85730 | <1% | 1,445 | $22.91 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,436 | $21.32 |
| J1815 | Injection, insulin, per 5 units | <1% | 585 | $20.65 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,593 | $18.53 |
| 96367 | <1% | 288 | $13.97 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 310 | $13.82 |
| 84100 | <1% | 469 | $12.79 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,149 | $12.23 |
| 12001 | <1% | 119 | $12.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,322 | $11.76 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 498 | $9.78 |
| 82010 | <1% | 40 | $9.58 | |
| 82565 | <1% | 172 | $5.93 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 91 | $5.62 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,378 | $5.37 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 557 | $4.09 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 550 | $3.43 |
| J7999 | Compounded drug, not otherwise classified | <1% | 749 | $2.48 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 814 | $0.24 |
| S0028 | Injection, famotidine, 20 mg | 0% | 422 | $0.00 |
| 84156 | 0% | 73 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 36 | $0.00 |
| 94664 | 0% | 46 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 266 | $0.00 |
| 84550 | 0% | 78 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 30 | $0.00 |
| 87210 | 0% | 322 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 118 | $0.00 |
| 73590 | 0% | 15 | $0.00 | |
| 97161 | 0% | 42 | $0.00 | |
| 97116 | 0% | 19 | $0.00 | |
| 84460 | 0% | 44 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 13 | $0.00 |
| 84112 | 0% | 21 | $0.00 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 35 | $0.00 |
| 84450 | 0% | 29 | $0.00 | |
| 84145 | 0% | 25 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 17 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 64 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 40 | $0.00 |
| 82570 | 0% | 16 | $0.00 | |
| 10060 | 0% | 16 | $0.00 | |
| 84439 | 0% | 37 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 13 | $0.00 |
| 84520 | 0% | 39 | $0.00 | |
| 80329 | 0% | 660 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 439 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 728 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,194 | $0.00 |
| 88304 | 0% | 203 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 370 | $0.00 |
| 94760 | 0% | 149 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 44 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 71 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 77 | $0.00 |
| 76830 | Ultrasound, transvaginal | 0% | 251 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 14 | $0.00 |
| 84132 | 0% | 41 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 138 | $0.00 |
| 94644 | 0% | 69 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 14 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 32 | $0.00 |
| 36410 | 0% | 14 | $0.00 | |
| 87070 | 0% | 32 | $0.00 | |
| 87205 | 0% | 33 | $0.00 | |
| 85652 | 0% | 59 | $0.00 | |
| 85018 | 0% | 35 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 101 | $0.00 |
| 76819 | Fetal biophysical profile; without non-stress testing | 0% | 18 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 29 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKELLAR, BRIAN (CEO)
Parent organizationBANNER HEALTH
| Provider | Location | Paid |
|---|---|---|
| Banner Baywood Medical Center | Mesa, AZ | $29.69M |
| Banner Goldfield Medical Center | Apache Junction, AZ | $18.63M |
| Banner Heart Hospital | Mesa, AZ | $340K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.